/ /

  • linkedin
  • Increase Font
  • Sharebar

    10-Question Quiz on PRECISION

    How well do you know the results?

    For many years, the major focus on the adverse events associated with the use of the non-steroidal anti-inflammatory drugs (NSAIDs) was on the gastrointestinal problems they could cause or exacerbate. More recently there has been a growing focus on cardiovascular (CV) problems, most notably myocardial infarction (MI) and stroke, that may be related to their use. Of special concern is the relative CV safety of the various NSAIDs and especially of the selective COX-2 inhibitors as opposed to the older non-selective NSAIDs.

    The Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION) cardiovascular safety study was ordered by the FDA more than a decade ago in response to these concerns. After 2 selective COX-2 inhibitors--rofecoxib and valdecoxib--were taken off the market for associations with increased CV morbidity, celecoxib manufacturer Pfizer was allowed to continue marketing the drug but was ordered to conduct the PRECISION trial. The results were first reported at the late-breaking clinical trials session at the American Heart Association annual meeting in November  and published simulatenously in the New England Journal of Medicine online.

    What do you know about the results?

    1. The recently released results of the PRECISION study on CV safety of celecoxib, naproxen, and ibuprofen found that:

    A. Celecoxib was inferior to naproxen and ibuprofen with regard to CV safety

    B.  All three of the medications were similar with regard to CV safety

    C. Ibuprofen was less likely than the other two medications to be associated with CV safety

    Answer and next question>>

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available